Novo Nordisk will pay China’s Jiangsu Hengrui Pharmaceuticals $300 million (€264 million) upfront, in a deal worth up to $2.6 billion (€2.3 billion), for rights outside Greater China to HRS-1596, an experimental obesity and diabetes pill that the companies say could be taken once a week.